|
|
Time |
Source |
|
Announcement
|
|
| 09 Dec 2019 |
7:45 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting |
| 06 Dec 2019 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy |
| 05 Dec 2019 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day |
| |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis tender offer for The Medicines Company commences |
| 24 Nov 2019 |
8:00 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death |
| 17 Nov 2019 |
3:45 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF |
| 15 Nov 2019 |
8:06 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease |
| |
11:27 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) |
| 12 Nov 2019 |
6:25 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment |
| |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
New Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis |
| 11 Nov 2019 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market |
| 05 Nov 2019 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez) |
| 01 Nov 2019 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis |
| 30 Oct 2019 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis announces AVXS-101 intrathecal study update |
| 24 Oct 2019 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in ankylosing spondylitis |
| 22 Oct 2019 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US |
| 08 Oct 2019 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept |
| |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept |
| 02 Oct 2019 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum |
| 01 Oct 2019 |
3:00 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence |
| 30 Sep 2019 |
6:20 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma |
| |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma |
| 29 Sep 2019 |
3:30 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients |
| |
3:30 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients |
| 19 Sep 2019 |
8:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1 |
| 18 Sep 2019 |
1:30 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Positive results from Novartis five-year VERIFY study in type 2 diabetes demonstrate long-term clinical benefits of early combination treatment with Galvus® and metformin |
| 17 Sep 2019 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis |
| 13 Sep 2019 |
1:15 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis |
| 03 Sep 2019 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine |
| 02 Sep 2019 |
7:30 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings |
| 01 Sep 2019 |
1:30 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint |
| 30 Aug 2019 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies |
| 09 Aug 2019 |
8:46 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case |
| 06 Aug 2019 |
11:08 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis stands behind Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy |
| 31 Jul 2019 |
3:05 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trials |
| 29 Jul 2019 |
6:00 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF) |
| 26 Jul 2019 |
1:06 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis receives positive CHMP opinion for Lucentis® treatment in preterm infants with retinopathy of prematurity (ROP), a disease causing visual impairment and blindness |
| 22 Jul 2019 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis |
| 18 Jul 2019 |
6:00 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased |
| 16 Jul 2019 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101) |
| 11 Jul 2019 |
9:30 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention |
| 01 Jul 2019 |
4:30 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio |
| 14 Jun 2019 |
7:30 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001) |
| 12 Jun 2019 |
6:20 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Cosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show |
| |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis Cosentyx® first to show efficacy in all key manifestations of psoriatic arthritis |
| 07 Jun 2019 |
6:00 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis announces new leader of Pharmaceuticals Business Unit |
| 06 Jun 2019 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible |
| 04 Jun 2019 |
6:00 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist® |
| 03 Jun 2019 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials |
| |
6:00 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Xolair® (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies |
| 01 Jun 2019 |
12:30 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial |
| 30 May 2019 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis' phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma |
| 24 May 2019 |
9:12 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer |
| |
5:42 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families |
| |
5:30 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA) |
| 23 May 2019 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis highlights company transformation, catalyst-rich pipeline, and strong progress on strategy at Meet Novartis Management investor event |
| 22 May 2019 |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment |
| 16 May 2019 |
2:00 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders |
| 08 May 2019 |
11:20 pm |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care |
| |
6:15 am |
GNW
|
|
|
Novartis International AG (0QLR) |
Novartis data at AAN show Mayzent's® positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS |